Immunology

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time

Monday, June 1, 2020 - 2:00am

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.

Key Points: 
  • Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.
  • The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment.
  • This announcement follows the identification of antibody candidates for an antiviral treatment which Celltrion completed in April.
  • In response to these positive results, Celltrion will now conduct additional efficacy and toxicity testing in pre-clinical settings and anticipates starting first-in-human clinical trials in July.

DGAP-News: After Scientific Breakthrough: Digid Seeks FDA Approval for Its Rapid Corona Antigen Test

Saturday, May 30, 2020 - 3:00am

With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device.

Key Points: 
  • With digid's point-of-care solution, the measurement results are transmitted wirelessly from a sensor hub to a mobile device.
  • What's more, the Digid Cantisense SARS-CoV-2 Test directly detects the presence of the virus while other rapid tests only recognize antibodies.
  • We have coated cantilevers with a capture layer of highly specific monoclonal antibodies, which can reliably bind SARS-CO-2 viruses in the test fluid."
  • Digital Diagnostics has applied for approval of the Digid Cantisense SARS-CoV-2 Test by the US Food and Drug Administration (FDA).

Dante Labs Launches Most-Affordable, Pan-European Coronavirus Tests for Current Infection (PCR Swab) and Antibodies

Friday, May 29, 2020 - 6:48pm

Dante Labs announced its new pan-European, COVID-19 tests for both antibodies and current infection with at-home collection kits and premium medical shipping - to help 300 million Europeans get back to normal life.

Key Points: 
  • Dante Labs announced its new pan-European, COVID-19 tests for both antibodies and current infection with at-home collection kits and premium medical shipping - to help 300 million Europeans get back to normal life.
  • LONDON, May 29, 2020 /PRNewswire/ -- Dante Labs announced today two new premium COVID-19 testing solutions, to identify antibodies and current infection (PCR swab) at affordable prices, to help people get back to normal life.
  • Dante Labs released premium tests, based on validated, certified technologies, with premium shipping and add-on services, at affordable prices.
  • Dante Labs leveraged its existing technology developed for whole genome sequencing and interpretation to quickly scale up a high-capacity, highly automated testing solution for both current infection and antibodies for COVID-19.

Immunotherapy Drugs Market Worth $274.6 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Friday, May 29, 2020 - 3:30pm

On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.

Key Points: 
  • On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.
  • The mAbs segment accounted for the largest share of the immunotherapy drugs market in 2019.
  • Cancer commanded the largest share of the immunotherapy drugs market, by therapeutic area, in 2019.
  • F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market.

Immunotherapy Drugs Market Worth $274.6 Billion by 2025 - Exclusive Report by MarketsandMarkets™

Friday, May 29, 2020 - 3:30pm

On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.

Key Points: 
  • On the basis of type, the immunotherapy drugs market is segmented into monoclonal antibodies, checkpoint inhibitors, interferons & interleukins, and other immunotherapy drugs.
  • The mAbs segment accounted for the largest share of the immunotherapy drugs market in 2019.
  • Cancer commanded the largest share of the immunotherapy drugs market, by therapeutic area, in 2019.
  • F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market.

Genekam Plasma Therapy Accelerator: a New solution for Better Antibody Therapy for All Coronavirus Patients

Friday, May 29, 2020 - 2:30pm

This will solve the shortage problem also of therapy as millions of persons recovered from coronavirus 2020 can donate the plasma many times a year.

Key Points: 
  • This will solve the shortage problem also of therapy as millions of persons recovered from coronavirus 2020 can donate the plasma many times a year.
  • SARS-Hunter is a quickest solution for creation of effective antibodies therapy with low costs for all patients around the world.
  • View the full release here: https://www.businesswire.com/news/home/20200529005307/en/
    Plasma Therapy Accelerator: a New Solution for Better Antibody Therapy for All Coronavirus Patients (Photo: Business Wire)
    Plasma from coronavirus recovered patients is being used as one of the successful therapeutic options to treat the corona virus-infected patients because it is rich in corona virus-specific antibodies.
  • SARS-hunter can have a very strong impact on the antibody therapy and should make available antibody therapy to a large population.

Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020

Friday, May 29, 2020 - 1:00pm

Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of ALT-P7, a HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-positive advanced breast cancer.

Key Points: 
  • Alteogen Inc. (KOSDAQ:196170) has today presented at ASCO results from the First-in-Human (FIH), phase 1 study of ALT-P7, a HER2-targeting antibody-drug conjugate (ADC), in patients with HER2-positive advanced breast cancer.
  • Patients with HER2-positive breast cancer who participated in this clinical trial had received 6 types of systemic chemotherapy, including 4 types of HER2-targeted therapy.
  • Alteogen Inc. is a Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics.
  • Alteogens portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexPTM-fusion and NexMabTM platform technology, respectively.

Alpine Immune Sciences Announces Poster Presentations at EULAR 2020

Friday, May 29, 2020 - 1:00pm

An abstract of the presentation will be available on the EULAR E-Congress 2020.

Key Points: 
  • An abstract of the presentation will be available on the EULAR E-Congress 2020.
  • CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases.
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients lives via unique protein engineering technologies.
  • Alpine is backed by world-class research and development capabilities, a highly productive scientific platform, and a proven management team.

Silverback Therapeutics Announces Presentation of Preclinical Data at ASCO Supporting Potential Clinical Activity of SBT6050 as a Single Agent and in Combination with Trastuzumab for the Treatment of HER2-Expressing Malignancies

Friday, May 29, 2020 - 1:00pm

In a HER2-positive human xenograft model, a combination of low dose SBT6050 mouse surrogate with trastuzumab greatly enhanced the anti-tumor activity observed with either agent alone.

Key Points: 
  • In a HER2-positive human xenograft model, a combination of low dose SBT6050 mouse surrogate with trastuzumab greatly enhanced the anti-tumor activity observed with either agent alone.
  • These data demonstrate the potential for clinical activity with SBT6050 as a single agent and in combination with trastuzumab in the setting of moderate or high HER2-expressing malignancies.
  • Our preclinical data continue to highlight the potential for single agent clinical activity with SBT6050 even in tumors with diminished or absent T-cell infiltrates, and the opportunity for enhanced activity in combination with trastuzumab.
  • We are encouraged by the preclinical data and plan to initiate clinical investigation of SBT6050 later this year.

CERTIFIED Air Cleaner Offers Reduction of Indoor Allergens in the Home

Friday, May 29, 2020 - 1:00pm

Design meets function with the virtually silent Cube Air Purifier, reducing dust and allergens for cleaner air in your home.

Key Points: 
  • Design meets function with the virtually silent Cube Air Purifier, reducing dust and allergens for cleaner air in your home.
  • It is important that the air cleaner can remove allergens from the air, and that these are captured in the filter of the air cleaner.
  • The Samsung Cube Air Purifier has met these standards and is CERTIFIED to reduce allergenic and irritant materials in the air.
  • "It's important for consumers with asthma or allergies to feel confident their air cleaner is capturing allergens and removing them from the indoor air."